ProfileGDS5678 / 1444632_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 76% 76% 81% 76% 81% 79% 77% 78% 76% 78% 79% 78% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1886777
GSM967853U87-EV human glioblastoma xenograft - Control 25.1880376
GSM967854U87-EV human glioblastoma xenograft - Control 35.1648176
GSM967855U87-EV human glioblastoma xenograft - Control 45.9234681
GSM967856U87-EV human glioblastoma xenograft - Control 55.1105876
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5936881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4380879
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2383477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3971178
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1106376
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3251878
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5136179
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3774578
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5473879